Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

Sen-Jam Pharmaceutical, a leader in innovative anti-inflammatory care, today announced the submission of a new patent application that introduces a novel composition and method to target obesity and ...

JPMorgan's annual survey of 40 executives shows that coverage of popular weight-loss drugs continues to slowly increase ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Popular medications, such as Ozempic, Mounjaro and Wegovy, are known as GLP-1 agonists as they mimic the natural GLP-1s ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Explore how inhibiting myostatin can promote muscle mass in men, addressing sarcopenia, GLP-1 medication effects, and aging ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...